Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06269393

A Study of IBI311 in Subjects With Steroid-resistant, Thyroid Associated Ophthalmopathy

Thyroid Associated Ophthalmopathy Clinical Trial

Official title:
An Exploratory Study of the Efficacy and Safety of IBI311, a Modified Anti-IGF-1R Antibody, in Patients With Steroid-resistant, Thyroid Associated Ophthalmopathy

Clinical Trial Summary

This is an exploratory study of the efficacy and safety of IBI311, a modified anti-IGF-1R antibody, in patients with steroid-resistant, thyroid associated ophthalmopathy (TAO). This study includes two stages. Stage I is a single-center, single-arm, open-label clinical study designed to evaluate the safety and tolerability of IBI311 in subjects with TAO. Approximately 10 subjects meeting the study eligibility criteria will be enrolled. Stage II is a single-center, randomized, double-masked, placebo-controlled clinical trial designed to evaluate the efficacy and safety of IBI311 in subjects with steroid-resistant TAO. Approximately 54 subjects meeting the study eligibility criteria will be randomly assigned to IBI311 or placebo on day 1 (D1) in a 2:1 ratio stratified by disease activity.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06269393
Study type Interventional
Source Peking University People's Hospital
Contact
Status Active, not recruiting
Phase Phase 3
Start date January 1, 2024
Completion date February 1, 2026
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT06087731 - Efficacy and Safety of Tocilizumab for TAO Phase 2
Recruiting NCT05110040 - Multi-model Image of Immunosuppressive Agents in TAO N/A
Recruiting NCT06112340 - A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Recruiting NCT03107078 - Using A Novel Classification System in Intravenous GCs Therapy of TAO: A Multi-central, Randomized, Open, Superior Trial Phase 4
Recruiting NCT04548284 - Study of Therapeutic Value of Periorbital Injection of Glucocorticoid in Mild TAO Phase 3
Recruiting NCT03515863 - Natural History and Risk Factors of TAO
Recruiting NCT06226545 - A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease Phase 2
Completed NCT00150111 - Rituximab in the Treatment of Graves' Disease Phase 1/Phase 2
Completed NCT03110848 - Effects of Atorvastatin in Graves' Orbitopathy (GO) Phase 2
Recruiting NCT04662190 - Evaluation of the Efficacy and Safety of 3D Printing for Orbital Surgery. N/A
Recruiting NCT05276063 - A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) Phase 2/Phase 3
Not yet recruiting NCT04919694 - Combination of Orbital Compression Surgery and Strabismus Surgery for Thyroid Associated Ophthalmopathy N/A
Recruiting NCT03131726 - Treatment of Graves´Ophthalmopathy With Simvastatin (GO-S) Phase 3
Completed NCT02766660 - Optic Disc, Macula, and Retinal Nerve Fiber Layer Measurements Obtained by OCT in Thyroid Associated Ophthalmopathy N/A
Not yet recruiting NCT03098225 - A Trial to Evaluate the Efficacy of Orbital Radiotherapy in Graves' Orbitopathy Phase 4
Recruiting NCT05112211 - Multi-model Image of Doxycycline in TAO N/A